Amdoxovir

Structural formula
General
Non-proprietary name	Amdoxovir
other names	2,6-diaminopurine-dioxolane (2 R , 4 R ) -4- (2,6-diamino-9 H -purin-9-yl) -2- (hydroxymethyl) -1,3-dioxolane
Molecular formula	C 9 H 12 N 6 O 3
External identifiers / databases
CAS number 145514-04-1 PubChem 124088 ChemSpider 110576 DrugBank DB06619 Wikidata Q460478
Drug information
Drug class	Antiviral agent , nucleoside reverse transcriptase inhibitors
Mechanism of action	Competitive inhibition of reverse transcriptase
properties
Molar mass	252.23 g · mol -1
safety instructions
GHS hazard labeling no classification available
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Amodxovir is an experimental drug used to treat HIV- infected patients as part of combination therapy for HIV .

Amodxovir belongs to a group of nucleoside reverse transcriptase inhibitors (NRTIs).

history

Amdoxovir was licensed to the pharmaceutical company Triangle by Emory University in 1996 . Triangle was acquired by Gilead in January 2003 . At this point in time, amdoxovir, also known as DAPD, was in phase II of clinical trials and, in addition to its use against HIV, was also being tested for its effectiveness against HBV . In 2004, Gilead ended a collaboration with Emory University to develop and commercialize amdoxovir. Emory University has expressed an interest in continuing to evaluate amdoxovir in clinical trials.

In the meantime, the development of the drug was continued by the US pharmaceutical company RFS Pharma , but has now been completely discontinued.

Side effects

Little is known about side effects. The observations from studies largely correspond to the side effects typical for NRTIs.

Resistances

Amdoxovir showed good activity in vitro against NRTI resistant strains (including Retrovir (AZT) and Epivir (3TC)). HIV with a mutation in K65R with resistance to Videx ( ddI ) and Viread ( tenofovir ) appear less susceptible.

Individual evidence

1. ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
2. ^ Gilead, Emory University and the University of Georgia Research Foundation End Licensing Agreement for Amdoxovir, Investigational Agent for HIV. In: gilead.com. Retrieved May 26, 2017 (English). 
3. ↑ ^{a b} Entry on aidsmeds.com ( Memento from April 5, 2007 in the Internet Archive )
4. ↑ Amdoxovir. In: AIDSinfo Drug Database. United States Department of Health and Human Services , accessed February 15, 2017 .